• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Bayer “Liberty Link” Maize Banned In Brazil

29/07/2010 by Intellectual Property Watch 1 Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

German biotechnology company Bayer has met resistance in Brazil where the Paraná Federal Court revoked the authorisation for the commercial release of the company’s “Liberty Link” genetically modified maize on 27 July, according to a press release posted on the website of one of the civil lawsuit complainants.

Described as a “landmark,” the ruling prohibits the marketing of the genetically modified maize because of a lack of post-release monitoring. The judge also revoked authorisation for this plant to be cultivated in the north and northeast of Brazil due to the lack of studies on potential impacts of the technology on the local biodiversity. The ruling also invalidates a previous approval given by the Brazilian National Biosafety Technical Commission (CTNBio) for the commercial release of the maize.

CTNBio is now under obligation to ensure comprehensive access to the procedures for the approval of GMOs. The civil lawsuit complainants were Terra de Direitos, the Agricultura Familiar e agroecologia, the Instituto Brasileiro de Defesa do Consumidor and the National Small Farmers’ Association, and mainly challenged the CTNBio’s approval of GM maize without proper biosafety regulations and environmental studies.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"Bayer “Liberty Link” Maize Banned In Brazil" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP-Watch Briefs, Language, English

Comments

  1. Agatha Wong says

    16/08/2010 at 9:32 am

    I wonder if Bayer would have been allowed to plant the GM maize in Europe under EU regulations. A very sensible decision by the Paraná Federal Court. Amazing (or perhaps not) that such a reputable company would want to take such an irresponsible step. Anything to keep the shareholders happy it seems.

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.